Transthyretin-mediated Amyloidosis with Polyneuropathy

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

FDA approval · 2019-05-03
FDA Approved: VYNDAQEL — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved VYNDAQEL (tafamidis meglumine) as the original application for the treatment of transthyretin-related familial amyloid polyneur…